Current cancer immunotherapies are primarily based on αβ T cells, which heavily rely on MHC-mediated presentation of tumor-associated peptides or unique neoantigens, thus limiting their effectiveness and applicability in various scenarios. Here, HLA-C is linked to neoplasm.